Milestone Scientific (MLSS) 주식 개요
마일스톤 사이언티픽은 미국, 중국 및 전 세계에서 진단 및 치료용 주사 기술과 의료 및 치과용 기기를 특허, 설계, 개발 및 상용화하는 바이오메디컬 기술 회사입니다. 자세히 보기
MLSS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Milestone Scientific Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$0.32 |
| 52주 최고가 | US$0.73 |
| 52주 최저가 | US$0.22 |
| 베타 | 1.02 |
| 1개월 변동 | -17.39% |
| 3개월 변동 | 5.16% |
| 1년 변동 | -56.02% |
| 3년 변동 | -63.27% |
| 5년 변동 | -86.34% |
| IPO 이후 변동 | -97.76% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 11
MLSS: Expanding Clinical Adoption And New Capital Raise Will Drive Upside
Analysts have maintained their $1.00 price target for Milestone Scientific, noting only minor adjustments to the discount rate, profit margin assumptions, and future P/E inputs, rather than any broad change in outlook. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue in the range of US$9.8 million to US$10.2 million, citing double digit growth driven by commercial adoption across dental and medical segments.내러티브 업데이트 • May 27
MLSS: Medical Adoption And New Capital Raise Will Support Future Upside
Analysts have adjusted their price target on Milestone Scientific to $1.00, supported by updated assumptions that include a slightly lower discount rate, revised revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue of US$9.8 million to US$10.2 million, tied to commercial adoption in both dental and medical segments (Corporate Guidance).Recent updates
내러티브 업데이트 • Jun 11
MLSS: Expanding Clinical Adoption And New Capital Raise Will Drive Upside
Analysts have maintained their $1.00 price target for Milestone Scientific, noting only minor adjustments to the discount rate, profit margin assumptions, and future P/E inputs, rather than any broad change in outlook. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue in the range of US$9.8 million to US$10.2 million, citing double digit growth driven by commercial adoption across dental and medical segments.내러티브 업데이트 • May 27
MLSS: Medical Adoption And New Capital Raise Will Support Future Upside
Analysts have adjusted their price target on Milestone Scientific to $1.00, supported by updated assumptions that include a slightly lower discount rate, revised revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue of US$9.8 million to US$10.2 million, tied to commercial adoption in both dental and medical segments (Corporate Guidance).내러티브 업데이트 • May 04
MLSS: Expanded Share Authorization And Private Placement Will Support Future Upside
Milestone Scientific's analyst price target has been adjusted slightly, with analysts pointing to small refinements in the discount rate, long term profit margin assumptions and future P/E expectations as key drivers of the updated valuation. What's in the News Entered a securities purchase agreement for a private placement of 7,962,963 units at $0.27 per unit, for gross proceeds of about $2.15m.내러티브 업데이트 • Apr 18
MLSS: Expanded Share Authorization Will Support Future Upside As Guidance And PE Strengthen
Analysts have adjusted their price target on Milestone Scientific to reflect a modest change in the assumed discount rate and profit margin. They are keeping fair value at $1.00 while updating their future P/E outlook to 72.06x based on the latest inputs.내러티브 업데이트 • Apr 03
MLSS: Expanded Share Authorization Will Support Future Upside As Revenue Guidance Strengthens
Analysts have modestly adjusted their price target on Milestone Scientific to reflect updated views on slightly different revenue growth expectations, profit margin assumptions and a revised forward P/E profile, while keeping the fair value estimate broadly aligned with prior levels in dollar terms. What's in the News Management issued earnings guidance for the year ending December 31, 2026, with expected total revenue in a range of US$9.8 million to US$10.2 million, citing broadening commercial adoption in both dental and medical segments (company guidance).내러티브 업데이트 • Mar 19
MLSS: Expanded Share Authorization Will Support Future Upside From Current Levels
Analysts have modestly adjusted their price target on Milestone Scientific to reflect updated views on discount rates, profit margins, and future P/E expectations, while keeping the fair value estimate unchanged at $1.00 per share. What's in the News The company filed a Certificate of Amendment to its Restated Certificate of Incorporation in Delaware on March 10, 2026, increasing authorized common stock from 100,000,000 to 125,000,000 (Key Developments).내러티브 업데이트 • Mar 05
MLSS: Shares Will Likely Rise As Expanded Authorization Supports Undervaluation
Analysts have modestly raised their price target on Milestone Scientific to $1.00. The change reflects slightly higher assumed discount rates and price-to-earnings expectations, along with a marginally lower profit margin outlook in their updated models.내러티브 업데이트 • Feb 18
MLSS: Shares Will Likely Rise As Share Authorization Supports Undervaluation
Analysts have nudged their price target on Milestone Scientific slightly higher to $1.00, reflecting small tweaks to the discount rate, profit margin assumptions, and future P/E inputs in their models. What's in the News Shareholders ratified the appointment of CBIZCPA P.C. as Milestone Scientific Inc.'s independent auditors for the fiscal year ending December 31, 2025, at the AGM held on December 18, 2025 (Key Developments).내러티브 업데이트 • Feb 03
MLSS: Shares Will Likely Rise As Increased Share Authorization Supports Undervaluation
Analysts have adjusted their price target on Milestone Scientific to align with updated assumptions around discount rates, profit margins, and future P/E expectations. This has led to a modest shift in the projected valuation range expressed in US$ terms.내러티브 업데이트 • Jan 20
MLSS: Shares Will Likely Rise As Auditor Approval Supports Undervaluation
Analysts have slightly lifted their price target on Milestone Scientific to around US$1.00, citing small tweaks to their discount rate, profit margin outlook, and a projected future P/E of about 71x as the main drivers of the updated view. What's in the News Shareholders approved CBIZCPA P.C. as Milestone Scientific Inc.'s independent auditor for the fiscal year ending December 31, 2025, at the AGM held on December 18, 2025 (AGM filing).내러티브 업데이트 • Jan 06
MLSS: Shares Will Likely Rise As Listing Plan Supports Undervaluation
Analysts have made a modest adjustment to their price target on Milestone Scientific, keeping fair value anchored at US$1.00 while fine tuning assumptions around discount rate, revenue growth, profit margin and future P/E to reflect updated views on the company’s risk profile and earnings power. What's in the News At the December 18, 2025 AGM, shareholders approved an amendment to Milestone Scientific's Restated Certificate of Incorporation to increase authorized common shares from 100,000,000 to 125,000,000 (AGM filing).내러티브 업데이트 • Dec 19
MLSS: Shares Will Likely Rise As Listing Compliance Risks Ease
Analysts have modestly increased their price target on Milestone Scientific to reflect a slightly lower perceived risk in future cash flows, despite trimming long term profit margin assumptions and applying a higher forward earnings multiple. What's in the News Proposed amendment to the Restated Certificate of Incorporation to increase authorized common shares from 100 million to 125 million, expanding potential equity financing capacity (company filing).내러티브 업데이트 • Dec 04
MLSS: Shares Will Likely Rebound As NYSE Compliance Plan Progresses
Analysts have trimmed their price target on Milestone Scientific from 1.13 dollars to 1.00 dollars, citing slightly slower expected revenue growth and a modestly lower valuation multiple. This is partially offset by stable profit margin assumptions and a marginally reduced discount rate.내러티브 업데이트 • Nov 20
MLSS: Shares Will Face Key NYSE American Compliance Decision by 2027
Analysts have revised their price target for Milestone Scientific downward from $1.63 to $1.13. They cite lower projected revenue growth and a higher discount rate as key factors influencing their updated outlook.내러티브 업데이트 • Aug 19
CompuFlo Epidural System Will Unlock New Global Opportunities
The downward revision in Milestone Scientific’s price target reflects materially lower revenue growth expectations, leading to a drop in projected fair value from $2.12 to $1.62. What's in the News Eric C.
새로운 내러티브 • Apr 07
CompuFlo Epidural System Will Unlock New Global Opportunities
Strategic partnerships and regulatory approvals are expanding market access for the CompuFlo Epidural System, potentially driving significant revenue growth.주주 수익률
| MLSS | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | -13.9% | 3.9% | -2.5% |
| 1Y | -56.0% | -19.9% | 19.0% |
수익률 대 산업: MLSS은 지난 1년 동안 -19.9%의 수익을 기록한 US Medical Equipment 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: MLSS은 지난 1년 동안 19%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| MLSS volatility | |
|---|---|
| MLSS Average Weekly Movement | 14.2% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: MLSS의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: MLSS의 주간 변동성(14%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1989 | 15 | Eric Hines | www.milestonescientific.com |
마일스톤 사이언티픽은 미국, 중국 및 국제적으로 의료 및 치과용 진단 및 치료 주사 기술과 장치를 특허, 설계, 개발 및 상용화하는 생의학 기술 회사입니다. 치과 및 의료 부문을 통해 운영됩니다. 이 회사는 국소 마취가 필요한 치과 시술을 위한 일회용 핸드피스 기기인 The Wand를 CompuDent 및 STA 단일 치아 마취 시스템이라는 이름으로 제공합니다.
Milestone Scientific Inc. 기초 지표 요약
| MLSS 기초 통계 | |
|---|---|
| 시가총액 | US$28.16m |
| 순이익 (TTM) | -US$4.57m |
| 매출 (TTM) | US$8.90m |
3.2x
주가매출비율(P/S)-6.2x
주가수익비율(P/E)MLSS는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| MLSS 손익계산서 (TTM) | |
|---|---|
| 매출 | US$8.90m |
| 매출원가 | US$2.58m |
| 총이익 | US$6.32m |
| 기타 비용 | US$10.89m |
| 순이익 | -US$4.57m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.052 |
| 총이익률 | 71.03% |
| 순이익률 | -51.30% |
| 부채/자본 비율 | 35.0% |
MLSS의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/28 12:12 |
| 종가 | 2026/06/26 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Milestone Scientific Inc.는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Bruce Jackson | Benchmark Company |
| Anthony Vendetti | Maxim Group |
| James Terwilliger | Northland Capital Markets |